📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Paradeep Phosphates Q3 Net Profit Falls 13% to ₹182 Cr; 9M Profit Jumps 71.6% Post MCFL Merger
Paradeep Phosphates (PPL) reported a mixed Q3 FY26 with total income rising 14.9% YoY to ₹5,779.7 crore, but net profit declining 13% to ₹182.1 crore due to higher material costs. The 9-month (9M) performance was significantly stronger, with net profit surging 71.6% to ₹840.7 crore and EBITDA growing 44.7% to ₹1,816.6 crore. The completion of the MCFL merger in October 2025 has expanded PPL's capacity to 3.7 MMTPA and strengthened its presence in Southern India. The company is now targeting a total capacity of 5.0 MMTPA by FY29 while pursuing 100% backward integration for phosphoric acid.
Key Highlights
9M FY26 Net Profit rose 71.6% YoY to ₹8,407 million; Total Income grew 34.1% to ₹172,311 million.
Q3 FY26 Net Profit declined 13% YoY to ₹1,821 million despite a 14.9% rise in Total Income.
Total fertilizer sales volume for 9M FY26 reached 3.36 million MT, a 16.9% YoY increase.
MCFL merger completed in Oct 2025, adding 23% capacity and diversifying the product basket with Urea.
Capex plan underway to expand granulation capacity to 5.0 MMTPA by FY29, funded via internal accruals and debt.
💼 Action for Investors
While Q3 saw margin pressure, the strong 9M growth and MCFL merger integration provide a solid foundation for long-term expansion. Investors should monitor the progress of backward integration projects at the Paradeep plant, which are critical for hedging global raw material price volatility.
Paradeep Phosphates Shareholders Approve Borrowing Limit Increase and New Board Appointments
Paradeep Phosphates Limited (PPL) has successfully passed five key resolutions through a postal ballot with overwhelming shareholder support. A significant resolution to increase borrowing limits and create charges on company assets was passed with 99.52% approval, providing the company with enhanced financial flexibility for future requirements. Additionally, shareholders ratified the appointment of two new directors and approved an alteration to the company's Memorandum of Association. The high voter turnout of 79.6% indicates strong alignment between the management and its large institutional and promoter base.
Key Highlights
Resolution to increase borrowing limits and create asset charges passed with 99.52% majority.
Appointment of Mrs. Ruchira Kamboj as Non-Executive Independent Director approved with 99.64% votes.
Alteration of the Memorandum of Association (MOA) object clause received 99.99% shareholder approval.
Total voting participation stood at 79.60%, representing 82.62 crore shares out of 103.79 crore total shares.
Appointment of Mr. Akshay Poddar as Non-Executive Director cleared with 97.74% support.
💼 Action for Investors
Investors should monitor the company's upcoming debt-raising activities and capital expenditure plans following the approved increase in borrowing limits. The high approval rates for all resolutions signal strong confidence in the current management and the company's strategic direction.
SPARC Receives Valuable US FDA Priority Review Voucher for Sezaby® Approval
Sun Pharma Advanced Research Company (SPARC) has been granted a Rare Pediatric Disease Priority Review Voucher (PRV) by the US FDA following the approval of Sezaby® for neonatal seizures. This voucher is a highly valuable asset that can be used to expedite the review of a future drug application or sold to another pharmaceutical company. Historically, PRVs have commanded market prices between $90 million and $110 million, representing a significant potential non-dilutive cash inflow. This milestone enhances SPARC's strategic flexibility and validates its R&D capabilities in the rare pediatric disease space.
Key Highlights
US FDA grants Rare Pediatric Disease Priority Review Voucher (PRV) associated with Sezaby® approval.
Sezaby® is a specialized formulation of phenobarbital sodium for treating neonatal seizures.
The PRV is a tradable asset that can be sold to third parties for significant capital or used for future priority reviews.
Receipt of the voucher provides SPARC with additional liquidity to accelerate its clinical pipeline.
The announcement confirms the successful regulatory pathway for SPARC's pediatric innovation.
💼 Action for Investors
Investors should monitor for any future announcements regarding the sale of this voucher, which could provide a substantial one-time cash boost. This development strengthens the company's balance sheet without equity dilution.
Paradeep Phosphates Q3 Revenue Up 15% to ₹5,749 Cr; 9M PAT Surges 71% to ₹841 Cr
Paradeep Phosphates (PPL) delivered a robust performance for Q3 FY26, with revenue growing 15% YoY to ₹5,749 crore and EBITDA rising 5% to ₹503 crore. The nine-month (9M) performance was particularly strong, with PAT surging 71% YoY to ₹841 crore and revenue increasing 34% to ₹17,124 crore. Growth was primarily driven by higher sales volumes in value-added NPK grades (up 30%) and TSP (up 107%). The company is also progressing on its backward integration strategy, expanding Phos Acid capacity to 0.7 MMTPA to improve long-term margins.
Key Highlights
9M FY26 PAT increased by 71% YoY to ₹841 crore, while EBITDA rose 45% to ₹1,817 crore.
Q3 FY26 Revenue from operations grew 15% YoY to ₹5,749 crore with production volumes up 13%.
NPK sales volumes grew 30% YoY in 9M to 17.51 lakh tonnes; TSP sales surged 107% to 2.43 lakh tonnes.
Phos Acid expansion from 0.5 to 0.7 MMTPA is underway to achieve 100% backward integration across sites.
Credit rating upgraded to AA, reflecting improved fundamentals and optimizing cost of capital for capex.
💼 Action for Investors
The strong volume growth in high-margin products and the move toward 100% backward integration are significant positives for long-term profitability. Investors should monitor the progress of the Phos Acid expansion and granulation debottlenecking as key drivers for future earnings.
Paradeep Phosphates Q3 PAT at ₹182 Cr; N Suresh Krishnan Re-appointed as MD & CEO
Paradeep Phosphates reported a 15.2% year-on-year increase in revenue to ₹5,748.67 crore for Q3 FY26. However, quarterly net profit declined to ₹182.05 crore from ₹209.28 crore in the previous year, primarily due to an exceptional item of ₹41.30 crore. On a nine-month basis, the company showed robust growth with PAT reaching ₹841.24 crore, up from ₹490.66 crore. The board also confirmed key leadership roles, re-appointing N Suresh Krishnan as MD & CEO and appointing K K Rajeev Nambiar as Joint MD.
Key Highlights
Revenue from operations increased to ₹5,748.67 crore in Q3 FY26 vs ₹4,989.55 crore in Q3 FY25.
Net profit for the quarter stood at ₹182.05 crore, impacted by a ₹41.30 crore exceptional charge.
9M FY26 PAT surged 71.4% to ₹841.24 crore compared to ₹490.66 crore in the previous year period.
N Suresh Krishnan re-appointed as MD & CEO for 3 years effective February 16, 2026.
Financial results reflect the merger with Mangalore Chemicals & Fertilizers Limited (MCFL) effective April 1, 2024.
💼 Action for Investors
Investors should focus on the strong nine-month growth trajectory and the successful integration of MCFL, while keeping an eye on the impact of exceptional items on quarterly margins. The leadership continuity is a positive sign for long-term strategic execution.
Paradeep Phosphates Q3 PAT at ₹182 Cr; Appoints K K Rajeev Nambiar as Joint MD
Paradeep Phosphates reported a 15.2% YoY increase in standalone revenue to ₹5,748.67 crore for Q3 FY26. However, quarterly net profit declined to ₹182.05 crore from ₹209.28 crore in the previous year, primarily due to an exceptional item of ₹41.30 crore. The nine-month performance remains robust, with PAT surging 71% to ₹841.24 crore compared to ₹490.66 crore in the same period last year. The company also announced leadership changes, including the re-appointment of N Suresh Krishnan as MD and the appointment of K K Rajeev Nambiar as Joint MD.
Key Highlights
Revenue from operations for Q3 FY26 stood at ₹5,748.67 crore, up from ₹4,989.55 crore YoY.
Net profit for the nine months ended Dec 2025 reached ₹841.24 crore, a significant jump from ₹490.66 crore YoY.
Quarterly PAT was impacted by an exceptional charge of ₹41.30 crore, resulting in a YoY dip to ₹182.05 crore.
Mr. N Suresh Krishnan re-appointed as MD for 3 years; Mr. K K Rajeev Nambiar appointed as Joint MD starting April 2026.
Financial results incorporate the retrospective impact of the MCFL merger effective from April 1, 2024.
💼 Action for Investors
Investors should look past the quarterly PAT dip caused by exceptional items and focus on the strong nine-month growth and successful MCFL integration. The strengthening of the top management team suggests a focus on long-term operational excellence.
Paradeep Phosphates Q3 PAT at ₹182 Cr; Re-appoints MD and Appoints New Joint MD
Paradeep Phosphates reported a revenue of ₹5,748.67 crore for Q3 FY26, a 15.2% increase compared to ₹4,989.55 crore in the same quarter last year. However, Net Profit for the quarter declined to ₹182.05 crore from ₹209.28 crore, primarily impacted by an exceptional item of ₹41.30 crore. On a nine-month basis, the company showed robust growth with PAT rising to ₹841.24 crore from ₹490.66 crore. The board also approved key leadership changes, including the re-appointment of N Suresh Krishnan as MD and the appointment of K K Rajeev Nambiar as Joint MD.
Key Highlights
Revenue from operations grew 15.2% YoY to ₹5,748.67 crore in Q3 FY26.
Net Profit for Q3 FY26 stood at ₹182.05 crore, down 13% YoY, affected by a ₹41.30 crore exceptional charge.
9-month PAT saw a significant jump of 71.4% to ₹841.24 crore compared to ₹490.66 crore in the previous year.
N Suresh Krishnan re-appointed as MD for 3 years; K K Rajeev Nambiar appointed as Joint MD.
Financials include the retrospective impact of the Mangalore Chemicals & Fertilizers Limited (MCFL) merger effective April 1, 2024.
💼 Action for Investors
Investors should focus on the strong 9-month growth trajectory and the long-term synergies expected from the MCFL merger despite the quarterly profit dip. The leadership continuity and expansion of the management team are positive signs for operational stability.
Paradeep Phosphates Q3 PAT Falls 13% YoY to ₹182 Cr; 9M Profit Surges 71% to ₹841 Cr
Paradeep Phosphates reported a 15.2% YoY increase in revenue to ₹5,748.67 crore for Q3 FY26, though net profit declined by 13% to ₹182.05 crore due to an exceptional loss of ₹41.30 crore. On a nine-month basis, the company showed strong performance with PAT rising 71.4% to ₹841.24 crore compared to the previous year. The financials reflect the impact of the completed merger with Mangalore Chemicals & Fertilizers Limited (MCFL), with figures restated from April 2024. Additionally, the board approved the re-appointment of N Suresh Krishnan as MD and the appointment of K K Rajeev Nambiar as Joint MD.
Key Highlights
Revenue from operations grew 15.2% YoY to ₹5,748.67 crore in Q3 FY26.
Net profit for Q3 FY26 stood at ₹182.05 crore, down from ₹209.28 crore in the same period last year.
9M FY26 PAT surged 71.4% YoY to ₹841.24 crore, driven by the MCFL merger integration.
Board approved re-appointment of N Suresh Krishnan as MD and K K Rajeev Nambiar as Joint MD for 3-year terms.
Financials include an exceptional loss of ₹41.30 crore during the quarter.
💼 Action for Investors
Investors should monitor the synergy benefits from the MCFL merger which are driving the strong 9M growth, despite the quarterly volatility. The management continuity with the MD's re-appointment provides stability for long-term strategy.
Park Medi World Q3 FY26: PAT Surges 40% to ₹1,968M; Bed Capacity to Reach 5,260 by FY28
Park Medi World reported a robust performance for 9M FY26, with revenue growing 17% YoY to ₹12,189 million and PAT increasing 40% to ₹1,968 million. The company is executing an aggressive expansion strategy, aiming to increase its bed capacity from 3,250 to 5,260 by FY28 through a mix of greenfield and brownfield projects. Operational efficiency improved as ARPOB rose to ₹27,406 and occupancy reached 65% despite the addition of new beds. Management targets a long-term EBITDA margin of 27% and an ROCE of 21%.
Key Highlights
9M FY26 Revenue grew 17% YoY to ₹12,189 million with an EBITDA margin of 26%.
Net Profit (PAT) for 9M FY26 surged 40% YoY to ₹1,968 million.
Bed capacity to expand by 660 beds in FY26 through projects in Agra and Panchkula, reaching 3,910 beds.
ARPOB improved to ₹27,406 from ₹25,500, while occupancy increased to 65% from 62% YoY.
Long-term guidance includes reaching 5,260 beds by FY28 with a target ROE of 23%.
💼 Action for Investors
Investors should focus on the company's ability to maintain margins during the rapid ramp-up of 2,000+ additional beds over the next two years. The efficient capex model of ₹3.4 million per bed makes this a high-growth play in the North Indian healthcare sector.
SPARC Issues Corrigendum for EGM; Promoter Stake to Rise to 69.31% via Warrants
Sun Pharma Advanced Research Company (SPARC) has issued a corrigendum to its EGM notice for the meeting scheduled on February 9, 2026, following observations from the NSE. The update clarifies the shareholding structure post-warrant conversion, indicating that promoter holding will increase from 65.67% to 69.31%. The company also provided technical reconciliations for its share capital, accounting for shares in abeyance and forfeited shares. There are no changes to the previously announced size, pricing, or structure of the warrants issue.
Key Highlights
Promoter holding to increase from 65.67% to 69.31% assuming full conversion of warrants.
Total equity share capital to expand from 32,45,21,588 to 36,30,31,588 shares post-allotment.
Public shareholding to be diluted from 34.33% to 30.69% following the issue.
Clarified a technical difference of 34,351 shares between issued and listed capital due to historical abeyance and forfeitures.
Confirmed no changes to the fundamental terms, pricing, or size of the proposed fundraise.
💼 Action for Investors
Investors should view the increased promoter stake as a sign of confidence, though it results in a ~3.6% dilution for public shareholders. Monitor the EGM results on February 9 for final approval of the warrant issuance.
Apar Industries Enters Telecom EPC Business with ₹156.9 Cr Railway Contract
Apar Industries is diversifying into the telecom service business, specifically targeting railway signaling and infrastructure. The company has secured a ₹156.9 crore EPC contract from South Eastern Railway for the deployment of telecom towers and OFC backbone across 1,563 route kilometers. This project supports the rollout of the 'Kavach' safety system and is expected to be completed within two years. The expansion requires minimal capex, with an estimated working capital requirement of only ₹10 crore.
Key Highlights
Awarded a ₹156.9 crore EPC contract from South Eastern Railway for telecom infrastructure
Project covers 1,563 route kilometers involving telecom towers and OFC backbone
Execution period is set for two years with a focus on the indigenous 'Kavach' safety system
Minimal capital expenditure required with an estimated working capital of ₹10 crore
Strategic entry into a new line of business to diversify revenue streams and deepen railway engagement
💼 Action for Investors
Investors should monitor the successful execution of this pilot-scale project as it opens doors to the massive 'Kavach' rollout across Indian Railways. This low-capex diversification into high-tech infrastructure is a positive strategic move for long-term growth.
Apar Industries Reports FY25 Revenue of ₹18,581 Cr with 30.6% 5-Year CAGR
Apar Industries has demonstrated robust growth with FY25 revenue reaching ₹18,581 crore, supported by a strong 5-year CAGR of 30.6%. The company maintains global leadership as the largest manufacturer of aluminum and alloy conductors and the third-largest producer of transformer oils. Export markets continue to be a significant driver, contributing 32.8% to the total FY25 revenue across 140+ countries. The conductor segment remains the primary growth engine, recording a 34.7% 5-year CAGR to reach ₹9,582 crore.
Key Highlights
FY25 consolidated revenue reached ₹18,581 crore ($2.20 billion) with a 30.6% 5-year CAGR.
Conductor segment revenue grew to ₹9,582 crore in FY25, achieving a 34.7% 5-year CAGR.
Export revenues accounted for 32.8% of total FY25 turnover, with operations spanning 140+ countries.
Strategic agreement with Hindalco for molten metal sourcing provides a cost saving of ₹1,200 per MT.
Successfully raised ₹1,000 crore through a QIP in 2024 to support greenfield expansions and growth.
💼 Action for Investors
Investors should view the company as a key beneficiary of global energy infrastructure and renewable energy spending. The strong export mix and cost-saving initiatives provide a competitive edge, making it a solid long-term hold in the industrial sector.
Apar Industries Q3 FY26 Revenue up 16.2% to ₹5,480 Cr; PAT grows 19.4% to ₹209 Cr
Apar Industries reported a strong Q3 FY26 with consolidated revenue reaching ₹5,480 crores, driven by domestic resilience and an improved product mix. Despite an exceptional loss of ₹25 crores due to new labour code provisions, PAT grew 19.4% YoY to ₹209 crores. The Conductor division was a standout performer, with EBITDA per MT surging 49.3% YoY to ₹44,195. While domestic revenue grew 30% YoY, exports faced headwinds, de-growing 11.2% in Q3 due to tariff-related challenges in the US market.
Key Highlights
9M FY26 revenue reached an all-time high of ₹16,299 crores, representing a 21.9% YoY growth.
Conductor division EBITDA per MT increased significantly to ₹44,195 in Q3 FY26 from ₹29,593 in Q3 FY25.
Specialty Oil and Lubricant division saw a 20.8% YoY volume growth in Q3 FY26.
Combined pending order book for Conductors and Cables stands at ₹9,064 crores.
Exceptional loss of ₹25 crores recorded for gratuity and compensated absences due to new labour code enactment.
💼 Action for Investors
Investors should maintain a positive outlook given the robust domestic demand and significant margin expansion in the conductor segment. Monitor the US export situation for signs of recovery as it remains a key high-margin geography.
Apar Industries Q3 FY26 Revenue Up 16% YoY to ₹5,480 Cr; PAT Grows to ₹208 Cr
Apar Industries reported a strong performance for Q3 FY26, with consolidated revenue from operations increasing by 16.2% YoY to ₹5,479.73 crore. Consolidated Profit After Tax (PAT) grew by 17.9% YoY to ₹207.61 crore, even after accounting for a one-time exceptional charge of ₹24.99 crore. The Conductors segment continues to lead growth, contributing ₹3,062.86 crore to the quarterly revenue. Additionally, the company strengthened its board by appointing Mr. Pitamber Shivnani as an Independent Director.
Key Highlights
Consolidated revenue from operations rose 16.2% YoY to ₹5,479.73 crore in Q3 FY26.
Consolidated PAT increased to ₹207.61 crore compared to ₹176.06 crore in Q3 FY25.
Recognized an exceptional item of ₹24.99 crore related to past service costs under the new Labour Codes.
Conductors segment revenue reached ₹3,062.86 crore, while Cables segment contributed ₹1,361.85 crore.
Nine-month FY26 consolidated revenue stands at ₹16,299.32 crore, up from ₹13,371.45 crore YoY.
💼 Action for Investors
Investors should focus on the robust growth in the Conductors and Cables segments, which indicates strong demand in the power infrastructure sector. The exceptional hit is a non-recurring regulatory adjustment, and the overall operational trajectory remains healthy.
Apar Industries Q3 FY26 PAT Rises 18% YoY to ₹208 Cr; Appoints New Independent Director
Apar Industries reported a strong performance for Q3 FY26 with consolidated revenue reaching ₹5,479.73 crore, a 16.2% increase from ₹4,716.42 crore in the previous year. Consolidated Profit After Tax (PAT) grew by 17.9% YoY to ₹207.61 crore, even after accounting for a one-time exceptional charge of ₹24.99 crore related to new labor code provisions. The Conductors segment led growth with revenues of ₹3,062.86 crore, while the board also approved the appointment of Mr. Pitamber Shivnani as an Independent Director.
Key Highlights
Consolidated Revenue from operations grew 16.2% YoY to ₹5,479.73 crore in Q3 FY26.
Consolidated PAT increased to ₹207.61 crore from ₹176.06 crore in the same quarter last year.
Conductors segment revenue rose significantly to ₹3,062.86 crore compared to ₹2,449.13 crore YoY.
Recognized an exceptional item of ₹24.99 crore for past service costs related to the Code on Social Security, 2020.
Appointment of Mr. Pitamber Shivnani as Independent Director (Non-Executive) approved by the Board.
💼 Action for Investors
Investors should take note of the robust double-digit growth in the Conductors and Cables segments, reflecting strong infrastructure demand. The one-time impact of labor code provisions is now largely priced in, making the underlying operational performance the key focus for future quarters.
Apar Industries Q3 FY26 PAT Rises 19.4% YoY to ₹208.9 Cr; Revenue Up 16.2%
Apar Industries reported a strong performance for Q3 FY26, with consolidated revenue from operations growing 16.2% YoY to ₹5,479.73 crore. Net profit for the quarter increased by 19.4% YoY to ₹208.93 crore, even after accounting for a one-time exceptional charge of ₹24.99 crore related to new Labour Code provisions. The Conductors segment continues to lead growth, contributing ₹3,062.86 crore to the top line. For the nine-month period, the company has already surpassed ₹723 crore in PAT, reflecting robust operational efficiency.
Key Highlights
Consolidated Revenue from Operations increased 16.2% YoY to ₹5,479.73 crore in Q3 FY26.
Profit After Tax (PAT) grew 19.4% YoY to ₹208.93 crore from ₹174.92 crore in the previous year.
Conductors segment revenue reached ₹3,062.86 crore, while Cables segment contributed ₹1,361.85 crore.
Exceptional item of ₹24.99 crore recognized due to provisions for the new Code on Social Security 2020.
Basic EPS for the quarter improved significantly to ₹52.01 from ₹43.55 in Q3 FY25.
💼 Action for Investors
Investors should remain positive on the stock as the company demonstrates strong growth in its core T&D segments despite regulatory cost headwinds. The consistent margin improvement and leadership in conductors make it a key beneficiary of global power infrastructure spending.
Park Medi World Q3 Revenue Up 18% to ₹4,100 Mn; 9M PAT Surges 43% with Strategic Acquisitions
Park Medi World reported a strong Q3 FY26 with revenue growing 17.76% YoY to ₹4,100 million and PAT increasing 15.78% to ₹528 million. The 9-month performance was particularly robust, with PAT surging 42.6% YoY to ₹1,968 million, supported by a 65% occupancy rate and improved operational efficiencies. The company aggressively expanded its footprint by acquiring KP Institute of Medical Sciences in Agra for ₹245 crore and Febris Hospital in Delhi. Management remains committed to a cluster-based expansion model, targeting a total capacity of 5,260 beds by March 2028.
Key Highlights
Q3 FY26 Revenue increased 17.76% YoY to ₹4,100 Mn with EBITDA margins expanding to 24.25%.
9M FY26 PAT grew by 42.60% YoY to ₹1,968 Mn, driven by higher patient volumes and better case mix.
Acquired 360-bed KP Institute of Medical Sciences in Agra for ₹245 crore in an all-cash deal.
Average occupancy ratio improved to 65% in 9M FY26 from 62% in the previous year.
Current bed capacity stands at 3,250 with a clear roadmap to reach 5,260 beds by March 2028.
💼 Action for Investors
The company's strong earnings growth and aggressive inorganic expansion into high-density urban catchments signal a positive growth trajectory. Investors should monitor the successful integration of the newly acquired Agra and Delhi assets to ensure margin stability.
Park Medi World Q3 Revenue Up 18% to ₹410 Cr; PAT Rises 16% with Strategic Acquisitions
Park Medi World reported a strong Q3 FY26 with revenue growing 17.76% YoY to ₹4,100 million and PAT increasing 15.78% to ₹528 million. The company maintained healthy EBITDA margins at 24.25% while integrating new capacities. Strategic growth was highlighted by the ₹245 crore acquisition of KP Institute in Agra and Febris Hospital in Delhi, bringing current bed capacity to 3,250. The management is executing a cluster-based expansion strategy with a target of 5,260 beds by March 2028.
Key Highlights
Q3 FY26 Revenue grew 17.76% YoY to ₹4,100 million; 9M FY26 PAT surged 42.6% to ₹1,968 million.
EBITDA margins improved to 24.25% in Q3 FY26 compared to 23.79% in the same quarter last year.
Acquired 360-bed KP Institute of Medical Sciences in Agra for ₹245 crore and 200-bed Febris Hospital in Delhi.
Average Revenue Per Occupied Bed (ARPOB) increased to ₹27,482 in Q3 FY26 from ₹26,206 in FY25.
Ambitious expansion roadmap to reach 5,260 beds by March 2028 from the current 3,250 beds.
💼 Action for Investors
Investors should focus on the successful integration and occupancy ramp-up of the newly acquired Agra and Delhi hospitals. The company's aggressive inorganic growth strategy and improving ARPOB make it a strong contender in the North Indian healthcare space.
Park Medi World Q3 FY26 Revenue Up 18% YoY; PAT Grows 16% to ₹528 Mn
Park Medi World reported a strong Q3 FY26 with revenue growing 18% YoY to ₹4,100 million and PAT increasing 16% to ₹528 million. The 9-month performance was even more robust, with PAT surging 43% YoY to ₹1,968 million, driven by improved occupancy of 65% and higher ARPOB of ₹27,406. The company is aggressively expanding its footprint, having recently acquired 560 beds through Febris Hospital and KPIMS. Management aims to reach a total capacity of 5,260 beds by March 2028, positioning the firm as a dominant player in North India.
Key Highlights
Q3 FY26 revenue rose 18% YoY to ₹4,100 Mn; EBITDA grew 20% to ₹994 Mn.
9M FY26 PAT surged 43% YoY to ₹1,968 Mn with a net margin of 16%.
Average Revenue Per Occupied Bed (ARPOB) increased 7.4% YoY to ₹27,406 in 9M FY26.
Strategic acquisitions of Febris Hospital (Delhi) and KPIMS (Agra) added 560 beds to the network.
Targeting a total capacity of 5,260 beds by March 2028 from the current 3,250 beds.
💼 Action for Investors
Investors should favor the strong operational metrics and aggressive inorganic expansion strategy. Monitor the integration of newly acquired hospitals and their impact on overall margins in the coming quarters.
Park Medi World Q3 PAT at ₹368.8M; Announces ₹3.3B in Strategic Acquisitions
Park Medi World Limited reported its first financial results post-listing, with Q3 FY26 consolidated revenue reaching ₹3,670.96 million and a net profit of ₹368.78 million. The company is aggressively pursuing inorganic growth, announcing acquisitions of K P S Wellness and SVPD Healthcare for ₹2,450 million, and Krishna Super-Speciality Hospital for ₹400 million. For the nine-month period ended December 2025, the group achieved a robust net profit of ₹1,671.67 million. IPO proceeds are being actively deployed, with ₹2,225.90 million already utilized for debt repayment and capital expenditure.
Key Highlights
Consolidated Q3 FY26 revenue stood at ₹3,670.96 million with a PAT of ₹368.78 million.
Announced acquisition of K P S Wellness and SVPD Healthcare for ₹2,450 million expected by Feb 2026.
Acquired Febris Multispeciality Hospital for ₹506.8 million via insolvency resolution process.
Approved acquisition of Mahip Hospital Private Limited (250 beds) for ₹400 million in January 2026.
Utilized ₹1,430.90 million of IPO proceeds for debt repayment to strengthen the balance sheet.
💼 Action for Investors
The company's aggressive M&A strategy and strong nine-month profitability suggest a high-growth trajectory post-IPO. Investors should monitor the successful integration of the newly acquired hospitals and their impact on consolidated margins.